ABCL

ABCL

USD

AbCellera Biologics Inc. Common Shares

$3.150-0.050 (-1.563%)

Echtzeitkurs

Healthcare
Biotechnologie
Kanada

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$3.200

Hoch

$3.310

Tief

$3.080

Volumen

8.00M

Unternehmensfundamentaldaten

Marktkapitalisierung

940.2M

Branche

Biotechnologie

Land

Canada

Handelsstatistiken

Durchschnittliches Volumen

4.49M

Börse

NMS

Währung

USD

52-Wochen-Spanne

Tief $1.891Aktuell $3.150Hoch $3.68

Ähnliche Nachrichten

Analyst Upgrades

Truist Securities Maintains Buy on AbCellera Biologics, Lowers Price Target to $10

Truist Securities analyst Robyn Karnauskas maintains AbCellera Biologics with a Buy and lowers the price target from $28 to $10.

Mehr anzeigen
Truist Securities Maintains Buy on AbCellera Biologics, Lowers Price Target to $10
BusinessWire

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

AbCellera anticipates starting the Phase 1 clinical trial for ABCL635 in Q3 2025 AbCellera (NASDAQ:ABCL) today announced it has received a No Objection Letter (NOL) from Health Canada authorizing its Clinical Trial

Mehr anzeigen
AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause
BusinessWire

AbCellera Reports Q1 2025 Business Results

AbCellera (NASDAQ:ABCL) today announced financial results for the first quarter of 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "After completion of a

Mehr anzeigen
AbCellera Reports Q1 2025 Business Results
BusinessWire

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Preclinical data on AbCellera's PSMA x CD3 T-cell engagers demonstrate potent anti-tumor activity and potential to further enhance function through costimulatory strategies AbCellera (NASDAQ:ABCL) today announced new

Mehr anzeigen
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025